Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Robert L. Ferris, Lisa Licitra, Jérôme Fayette, Caroline Even, George R. Blumenschein, Kevin Harrington, Joel Guigay, Everett E. Vokes, Nabil F. Saba, Robert I. Haddad, Shanmugasundaram Ramkumar, Jeffrey Russell, Peter Brossart, Makoto Tahara, Manish Monga, Jin Zhu, A. Dimitrios Colevas, Maura L. Gillison
Institutions: University of Pittsburgh Medical Center, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Centre Léon Bérard, Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Centre Antoine Lacassagne, University of Chicago Medical Center, Winship Cancer Institute, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University Hospital Southampton NHS Foundation Trust, Moffitt Cancer Center, University Hospital Bonn, National Cancer Center Hospital East, Bristol-Myers Squibb (United States), Stanford University, The Ohio State University
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2804290575